Cancer dormancy: opportunities for new therapeutic approaches.
about
Cancer as an evolutionary and ecological processActivation of the Syk tyrosine kinase is insufficient for downstream signal transduction in B lymphocytes.Recent translational research: computational studies of breast cancerTranscriptional changes induced by the tumor dormancy-associated microRNA-190Two host factors regulate persistence of H7-specific T cells injected in tumor-bearing mice.The intraportal injection model: a practical animal model for hepatic metastases and tumor cell dissemination in human colon cancerNew concepts in breast cancer emerge from analyzing clinical data using numerical algorithmsPerspective: tumour spread--the problems of latency.Detection and clinical importance of micrometastatic disease.Paclitaxel-induced cell death: where the cell cycle and apoptosis come together.A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype.A cellular automaton model for tumor dormancy: emergence of a proliferative switch.Consensus micro RNAs governing the switch of dormant tumors to the fast-growing angiogenic phenotype.Prospective identification of glioblastoma cells generating dormant tumors.Persistence of transcriptionally silent BCR-ABL rearrangements in chronic myeloid leukemia patients in sustained complete cytogenetic remission.Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment.Complex roles of tissue inhibitors of metalloproteinases in cancer.Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.VaccImm: simulating peptide vaccination in cancer therapy.Controversies in clinical cancer dormancyDormant Wnt-initiated mammary cancer can participate in reconstituting functional mammary glands.Mathematical models of cancer dormancy.N-acetylglucosaminyl 1-phosphate transferase: an excellent target for developing new generation breast cancer therapeuticMaintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer.p53 gene mutations are not required for early dissemination of cancer cells.Late pulmonary metastases of renal cell carcinoma immediately after post-transplantation immunosuppressive treatment: a case reportThe tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cellsAn anticancer strategic dilemma: to kill or to contain. The choice of the pharmaceutical industry in 2009.Building on the foundation of daring hypotheses: using the MKK4 metastasis suppressor to develop models of dormancy and metastatic colonization.Cancer immunoediting in malignant glioma.Cancer stem cells, tumor dormancy, and metastasis.Importance of a factor VIIIc-like glycoprotein expressed in capillary endothelial cells (eFactor VIIIc) in angiogenesis.The sudden presentation and progression of overt cervical metastases following treatment of head and neck cancers.Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy.Genetic protection of repopulating hematopoietic cells with an improved MDR1-retrovirus allows administration of intensified chemotherapy following stem cell transplantation in mice.The coming of age of tumour immunotherapy.Late recurrence after resection of mass-forming intrahepatic cholangiocarcinoma: report of a case.Analysis of a "phase transition" from tumor growth to latency.Disseminated tumor cells in the blood of patients with gastric cancer are an independent predictive marker of poor prognosis.
P2860
Q22122026-C5BBCD37-3F48-4080-AB15-A69F54B738C3Q24794791-8B81F192-5B59-4A71-B41E-CF2ED79157B4Q24797101-1A5F4EBF-2145-467F-89D3-F407FF123548Q28383492-0F4B059E-730F-4EB2-84CA-B3DD1E048257Q33398031-E4A4A132-A08F-47C7-AF36-6C08823C0635Q33402672-90D4F564-F9F8-4F4B-91D3-158498457D9CQ33445553-E3648E7A-BEA6-44AB-B77C-1EE77010B4D7Q33643346-6D20337F-6007-41B7-B1DD-7270FC50E214Q33678970-B24FF11D-F79B-4EB8-BB3E-8631164B5AD5Q33947088-1BE4DC74-2EAB-4D38-B11E-9E6C51013349Q34296481-C20B27D4-599E-4A08-B658-C93F62846754Q34351959-02E5C247-5490-4D9B-BB18-C95E275BA8DEQ34406041-371E5A2C-0D2C-4955-B4EA-F272F97812F1Q34412360-A4A43916-D852-410F-BC14-AF594DB919E5Q34430371-0FEB50D0-E848-485B-A1C5-F003319A502CQ34573041-A14DB665-0C1F-4584-A5E0-327029FBC86BQ34596110-698C934F-97D7-46B1-9967-6C37EBA8C26AQ34605219-84BCB9CE-7DDC-4D1E-AACE-83060611295EQ34668228-1534446F-77F8-4D7E-9316-6CAD23E4EA77Q35134139-975B53AE-1259-4633-A5C9-66A779B6250CQ35641656-62BF67A9-CE82-4A9F-9B1E-41CDE8971A12Q35994960-E49663BA-D9A1-44E6-8F76-96E325464ECBQ36156434-C35D81B7-4E5B-44AE-8E9F-3D27DFAFFFD3Q36352105-B7C715C6-96C8-4B0B-AB9B-95BFD6D4E8FEQ36386111-EE2894EA-D079-4E75-A60C-813B9A4206D2Q36608959-0F953726-1E04-43FC-8AB3-AF8C531DDE59Q36972761-41C4FC70-C78B-4AF7-A049-280F83B3D194Q37770597-E57A8F58-9635-47C3-894E-855D96AAE4DEQ37934033-B59367CA-8F61-4D15-8102-8C8B3CDE1B99Q37986999-81B2A574-F497-4A70-B097-5D836BD47491Q38056500-9CBDD07C-9CB6-4067-A4E3-4C715431FA3DQ41992284-90837EA3-4440-4085-A0FD-ABA3FD687A5EQ42561569-6C6E3C20-3F94-4B47-82F8-958C86C83AD6Q43540161-095B77F3-E2E9-4438-B956-D74612C4252BQ43938071-BE2C89AB-106C-4997-BB5A-3A4C59F5EFB9Q47603527-2E5FC41A-D2F8-46BE-8513-26A4A59ED997Q51311016-3F7716E9-CBC8-411B-85B8-B570B43AFA1EQ52070855-1EBBA012-446C-41FD-BD07-8D05E7B1A121Q54648079-E99F12E7-FBD5-438A-948B-D709C37A3278
P2860
Cancer dormancy: opportunities for new therapeutic approaches.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Cancer dormancy: opportunities for new therapeutic approaches.
@en
type
label
Cancer dormancy: opportunities for new therapeutic approaches.
@en
prefLabel
Cancer dormancy: opportunities for new therapeutic approaches.
@en
P2093
P2860
P356
P1433
P1476
Cancer dormancy: opportunities for new therapeutic approaches.
@en
P2093
P2860
P2888
P304
P356
10.1038/NM0597-505
P407
P577
1997-05-01T00:00:00Z